Clinical Trials

UVA Health System frequently opens new clinical trials, offering your patients the latest investigational treatments.

For a complete list of active trials and study coordinator contact information, visit uvahealth.com/clinicaltrials.

New Trials Available at UVA

Myasthenia Gravis (IRB-HSR #190089)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis (NCT04115293)

Primary Investigator: Sarah Jones

Clinical Research Coordinator: Mary Wagoner

Gynecologic Cancer (IRB-HSR #200011)

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression (NCT04209855)

Primary Investigator: Linda Duska

Clinical Research Coordinator: Benjamin Prabhu

Parkinson's Disease (IRB-HSR #200045)

A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson’s Disease (NCT04291014)

Primary Investigator: Binit Shah

Clinical Research Coordinator: Stephanie Lowenhaupt

Cervical Cancer (IRB-HSR #200129)

A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix (NCT03556839)

Primary Investigator: Linda Duska

Clinical Research Coordinator: Anne Gabel

Leukemia (IRB-HSR #200133)

Palliative Care Oncology in Relapsed, Refractory, and High-Risk Leukemia Patients: Randomized Phase II Study (NCT04482894)

Primary Investigator: Karen Ballen

Clinical Research Coordinator: Emily Leytham

Gastrointestinal Cancer (IRB-HSR #200139)

A phase 3, open-label, randomized study of futibatinib versus germcitabine-cisplatin chemotherapy as first-line treatment of patients with advanced cholagiocarcinoma harboring FGFR2 gene rearrangements (FOENIX-CCA3) (NCT04093362)

Primary Investigator: Paul Kunk

Clinical Research Coordinator: Sallie Mannen

Thoracic Oncology (IRB-HSR #200159)

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC (NCT04092283)

Primary Investigator: Richard Hall

Clinical Research Coordinator: Gracie Hockenberry

Ovarian Cancer (IRB-HSR #200181)

A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies with a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer (NCT04493619)

Primary Investigator: Linda Duska

Clinical Research Coordinator: Anne Gabel

 

Ovarian Cancer (IRB-HSR #200215)

A non-randomized prospective clinical trial comparing the noninferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers (SOROCk) (NCT04251052)

Primary Investigator: Kari Ring

Clinical Research Coordinator: Rachel Lacy

Ovarian Cancer (IRB-HSR #200252)

A randomized phase 2 study of bevacizumab and either weekly anetumab ravtansine or weekly paclitaxel in platinum resistant ovarian cancer (NCT03587311)

Primary Investigator: Linda Duska

Clinical Research Coordinator: Anne Gabel